From Financial Modeling Prep: 2025-04-01 06:17:00

Pfizer’s bivalent RSV vaccine, ABRYSVO®, receives an expanded indication from the European Commission to prevent lower respiratory tract disease caused by RSV in individuals aged 18-59, broadening its coverage in the EU.

ABRYSVO now offers protection against RSV-related hospital admissions in adults and passive protection for infants when maternal immunization occurs between weeks 24-36 of pregnancy.

Positive results from the MONeT trial led to this expanded authorization, highlighting the vaccine’s safety, immunogenicity, and effectiveness in adults at risk of RSV-associated LRTD.

RSV is a highly contagious virus causing significant public health burden with 158,000 adult hospital admissions annually in the EU, making ABRYSVO’s broad protection against RSV-A and RSV-B subgroups crucial in combating this potentially life-threatening virus.

Pfizer’s expanded authorization for ABRYSVO reflects the company’s commitment to addressing RSV challenges, aiming to reduce disease burden by protecting a wider segment of the population in future seasons.



Read more at Financial Modeling Prep:: Pfizer’s ABRYSVO Receives Expanded EU Authorizatio…